← Oncology Approval Tracker

FDA DECISION ·

Welireg

belzutifan · Merck

FDA approvalNew or expanded indicationRenal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For advanced renal cell carcinoma after treatment with a PD-1 or PD-L1 inhibitor and a VEGF-directed tyrosine kinase inhibitor.

LAMPGEN ANALYSIS

Why it matters

This decision brought HIF-2α inhibition into a post-immunotherapy and post-VEGF setting.

What research teams should watch

Verify both prior therapy classes and plan hemoglobin and oxygen-saturation monitoring.

PRIMARY RECORDS

Sources